 |
| Jeffrey Sturchio |
Jeffrey Sturchio is joining Finn Partners’ health policy and impact group as senior advisor to counsel clients on the issues shaping global health and innovation access.
He has held leadership positions at Merck & Co.; Global Health Council; Rabin Martin; and the Friends of the Global Fight Against AIDS, TB and Malaria, strengthening cross-sector partnerships and advancing collaborative approaches to some of the world's most pressing health challenges.
Sturchio will work closely with Mark Chataway, managing partner of the Impact Group. He said adding Sturchio’s “experience further strengthens our ability to help clients navigate increasingly complex policy, partnership and stakeholder issues.”
Formerly known as Hyderus, the Impact Group’s initiatives shape dialogue and inspire action on policy matters such as financing, access and the changing face of care provision.
Finn Partners ranks No. 7 in O’Dwyer’s healthcare rankings with 2025 fee income of $59.3M.
A breakthrough is not successful merely because it works. It succeeds when people and health systems can actually use it.
Jim Weiss, founder & chairman of Real Chemistry, has joined the board of ICR Inc. as it steps up its healthcare capital markets offering.
Ruder Finn has hired Kelly Yoder, who spent a dozen years at Weber Shandwick rising to North America health lead, as managing director, global head of health & life sciences.
ICR has named John Capodanno head of US healthcare corporate communications and Matthew Willey managing director in its medical technology and diagnostics practice. 
April is National Minority Health Month, spotlighting the urgency to improve health outcomes in communities of color.
